» Articles » PMID: 38696058

Predicting Factors and Clinical Outcome of Biochemical Incomplete Response in Middle Eastern Differentiated Thyroid Carcinoma

Overview
Journal Endocrine
Specialty Endocrinology
Date 2024 May 2
PMID 38696058
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The aim of this study was evaluate biochemical incomplete response (BIR) in Middle Eastern differentiated thyroid cancer (DTC), identify factors that could predict BIR before radioactive iodine (RAI) ablation and to investigate the long-term clinical outcome of DTC patient exhibiting BIR to initial therapy.

Methods: We retrospectively evaluated 1286 DTCs from Middle Eastern ethnicity who underwent total thyroidectomy and RAI therapy. Demograpic and clinico-pathological factors predicting BIR were evaluated. The outcome of these patients was analyzed using primary outcome of structural disease and disease-free survival (DFS).

Results: With a median follow-up of 10 years, 266 (20.7%) patients had BIR. High pre-ablation stimulated thyroglobulin (presTg), presence of lymph node metastasis, male gender and delayed initial RAI therapy (≥3 months) after thyroidectomy were significant independent predictors of BIR. Upon evaluating long-term clinical outcomes in 266 patients with BIR, we found 36.8% of patients developed structural disease. Male sex (OR = 1.56; 95% CI = 1.05-2.30; p = 0.0272) and increasing Tg after initial therapy (OR = 4.25; 95% CI = 1.93-10.82; p = 0.0001) were independent risk factors for structural disease in patients with BIR. DFS was significantly worse if both these risk factors existed concomitantly (p < 0.0001).

Conclusion: To achieve the fair efficacy of RAI therapy, early prediction of BIR before RAI ablation is desirable. Our finding of the clinico-pathological factors (high presTg level, LNM, delayed RAI therapy and male gender) could serve as easy and robust early predictors of BIR. In addition, DTC patients exhibiting BIR had a high risk of structural disease and hence personalized management approach would be preferable for BIR patients to ensure best clinical outcome.

Citing Articles

Gene Polymorphisms (rs2070744 and rs1799983) and Differentiated Thyroid Cancer: Investigating Associations with Clinical Outcomes.

Tiuca R, Pop R, Tiuca O, Banescu C, Carstea A, Preda C Int J Mol Sci. 2025; 26(2).

PMID: 39859471 PMC: 11765836. DOI: 10.3390/ijms26020759.


Comparing therapeutic outcomes: radioactive iodine therapy versus non-radioactive iodine therapy in differentiated thyroid cancer.

Tiuca R, Tiuca O, Pop R, Pascanu I Front Endocrinol (Lausanne). 2024; 15:1442714.

PMID: 39371921 PMC: 11452844. DOI: 10.3389/fendo.2024.1442714.

References
1.
Tuttle R, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M . Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid.... Thyroid. 2010; 20(12):1341-9. PMC: 4845674. DOI: 10.1089/thy.2010.0178. View

2.
Li H, Zhang Y, Wang C, Zhang X, Li X, Lin Y . Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer. Clin Endocrinol (Oxf). 2018; 88(4):601-606. DOI: 10.1111/cen.13551. View

3.
Ora M, Nazar A, Mishra P, Barai S, Arya A, Pradhan P . Factors predicting the risk of biochemical incomplete response in well-differentiated thyroid cancer after total thyroidectomy. Nucl Med Commun. 2021; 42(11):1187-1194. DOI: 10.1097/MNM.0000000000001448. View

4.
Webb R, Howard R, Stojadinovic A, Gaitonde D, Wallace M, Ahmed J . The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab. 2012; 97(8):2754-63. DOI: 10.1210/jc.2012-1533. View

5.
Siraj A, Parvathareddy S, Pratheeshkumar P, Divya S, Al-Sobhi S, Al-Dayel F . PD-L1 Is an Independent Prognostic Marker in Middle Eastern PTC and Its Expression Is Upregulated by Mutation. Cancers (Basel). 2021; 13(3). PMC: 7867170. DOI: 10.3390/cancers13030555. View